# Strengthening Status — 2026-10-02

## Baseline and disposition

Repository inspected at `664a4dba97b74df4430a03923acc5e0975bebee4` (v1.0.7), clean checkout,
no AGENTS.md present. The supplied September 16 attachments are older than the current source.
Keep current discovery, focused output, project/BA reasoning, and event-semantics improvements.

| Finding | Current-source disposition | Action/evidence |
|---|---|---|
| V01 | Already addressed in instructions | Existing discovery gate, two-round default and question limits; behavior still needs evaluation |
| V02 | Already addressed in instructions | Existing analysis statuses and approval boundary retained |
| V03 | Confirmed | Replaced generic source hierarchy with claim-specific applicability/conflict handling |
| V04 | Partially addressed | Existing blocker definitions retained; added hold-only-affected-conclusion rule |
| V05 | Confirmed | Added untrusted-source boundary and ST-01 case |
| V06 | Confirmed | Added security/privacy reference and direct routing |
| V07 | Partially addressed | Existing semantics rules retained; corrected ambiguous knowledge-base flow |
| V08 | Partially addressed | Existing proposed-status rule retained; expanded requirement template/fields |
| V09 | Confirmed | Frozen protocol, strict judge validation, one report/exit gate and offline regression tests |
| V10 | Evidence gap narrowed | Required release artifacts exist; historical manual review is not a new live benchmark |
| V11 | Partially addressed | Existing hazard register retained; linked causal reasoning in safety reference |
| V12 | Confirmed in reference | Added lifecycle, cancellation, replay and stale-state checks, ST-03 |
| V13 | Partially addressed | Added downtime entry/exit and final-state recovery gates |
| V14 | Partially addressed | Added execution provenance and planned/passed separation |
| V15 | Partially addressed | Existing non-pharmacy IS cases retained; added incident ST-06 and scope limits |
| V16 | Confirmed | Added claim/version/applicability/freshness record and verification limitations |
| V17 | Already addressed in instructions | Existing four-section default and focused output rules retained; added omission labels |
| V18 | Partially addressed | Existing routing retained/extended, mirrors checked, document versions distinguished |

## Validation boundary

The changes above implement instruction and tooling fixes; they do not demonstrate every behavior.
Local package/registry/unit tests and fresh-thread forward samples are separate evidence categories.
Full comparative release gate requires three recorded full-suite runs and independent adjudication.
No OPENAI_API_KEY or DEEPSEEK_API_KEY was available locally at initial inspection. Repository secret
availability was not inspected or inferred. Do not call an unavailable API run a model failure.
No marketplace/mobile installation or actual clinical workflow validation was performed.

## Next execution

Executed locally: 75-file package checks before adding the sample record, 49-case registry validation,
14 evaluator unit tests, and whitespace/diff checks. Three fresh-thread single samples were reviewed;
their requests and full outputs are retained in `FORWARD_SAMPLES_2026-10-02.md`. All three met their
checked behaviors; no comparative score or release pass is claimed. A local full API run was attempted
and stopped before model calls because no configured evaluation key was available.

Run package, registry and unit checks. Execute the frozen full protocol when an authorized live
provider is available, retain outputs separately for each run, fix actual failures, and rerun before
claiming release readiness. Do not fabricate comparative improvement from manual instruction review.
